Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
INAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $1.74
Previous CloseN/A
Volume363.43K
Average Volume (3M)9.81M
Market Cap
$19.51M
Enterprise Value$14.25M
Total Cash (Recent Filing)$610.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 13, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding72,483,250
10 Day Avg. Volume3,334,814
30 Day Avg. Volume9,813,893
Standard Deviation0.28
R-Squared0.00007
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.70
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$3.73Price Target Upside1281.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessINB-100 treated AML patients demonstrate 100% survival and complete remission at a median follow-up of 20.1 months.
Safety ProfileINB-100 is showing a clean safety profile with no treatment-related deaths, providing a benefit in progression-free survival and overall survival beyond HSCT.
Bears Say
Funding ConcernsCapital overhang remains the key concern, with the company having $10.2 million in cash and equivalents and a cash burn rate exceeding $6 million per quarter.
---
Ownership Overview
32.66% Insiders
2.38% Mutual Funds
30.19% Other Institutional Investors
32.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $0.22 and its highest was $1.74 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $19.51M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Mar 13, 2025 which is in 9 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Nov 12, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.02.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.07.
How many shares outstanding does IN8bio have?
IN8bio has 72,483,250 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -8.571%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
---
Company Description
IN8bio
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
---
INAB Stock 12 Month Forecast
Average Price Target
$3.73
▲(1281.48% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering INAB
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-53.39%
reiterated a buy rating 20 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.39% per trade.
---